AzTrials
AzTrials

Neonatal SepsisNCT03880305

White Blood Cells and Platelets Indices as a Prognostic Factor in Neonatal Sepsis

An observational study of Neonatal Sepsis, run by Assiut University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Sepsis is a complex condition initiated by a pathogen and mediated by cytokines followed by immune, inflammatory, and coagulation homeostasis disturbances, its evolution being dictated by a complicated balance between pro inflammatory and anti- inflammatory factors. Read more about this study

Who is it for?
Ages 1 day to 30 days
Conditions the study is for
Neonatal Sepsis
What is being tested?
complete blood count
How many people
100 participants
Where
1 siteEgypt
Study dates
1 Apr 2019to 31 Mar 2020
How long will I take part?
10 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 30 days
  • All sexes
  • No healthy volunteers
  • Child

Study population: newborns with neonatal sepsis

Who may be able to join

  • Neonates with suspected sepsis that show non-specific signs and symptoms or focal signs of infection, including temperature instability, hypotension, poor perfusion with pallor and mottled skin, metabolic acidosis, tachycardia or bradycardia, apnoea, respiratory distress, grunting, cyanosis, irritability, lethargy, seizures, feeding intolerance, abdominal distention, jaundice, petechiae, purpura, and bleeding. Later complications of sepsis might include respiratory failure, pulmonary hypertension, cardiac failure, shock, renal failure, liver dysfunction, cerebral edema or thrombosis, adrenal hemorrhage or insufficiency, bone marrow dysfunction (neutropenia, thrombocytopenia, anemia), and disseminated intravascular coagulation.
  • Cases with neonatal sepsis diagnosed by isolating the causative agent from a normally sterile body site (blood, CSF, urine, pleural, joint, and peritoneal fluids (Andi L Shaneetal, 2017).

Who cannot join

  • Obvious features of dehydration
  • Major congenital malformations.
  • GIT functional or organic obstruction, hematological disorders, hypersplenism, respiratory distress, malignancy and neurological emergency as intra cranial hemorrhage.
  • Hypoxic ischemic encephalopathy.
  • Post-surgical cases which need NICU observation.

Trial locations and contacts

1 site in 1 country.

Eslam A Roshdy contact

00201066962696

iroshdy92@gmail.com

Egypt1 site
  • Eslam Ahmad Roshdy

    Asyut

    Eslam A Roshdy, Physician, 00201066962696, iroshdy2@gmail.com

Other trials in Egypt

About this study

Sepsis is a complex condition initiated by a pathogen and mediated by cytokines followed by immune, inflammatory, and coagulation homeostasis disturbances, its evolution being dictated by a complicated balance between pro inflammatory and anti- inflammatory factors. Most of the short and long-term complications of the neonatal sepsis are strictly related to inflammatory mediators. Neonatal sepsis is associated with a mortality rate that ranges from 13 to 60% inspite of improved antibiotic therapy and an increased morbidity in survivors .

Read the detailed description

"Suspected sepsis" is one of the most frequently encountered diagnosis in neonatology because: a) a large number of newborns are evaluated for early or late sepsis based on risk factors and for fear of missing a correct diagnosis and a prompt treatment ; b) in neonates, the clinical signs of infection are not specific, late, and the differential diagnosis with neonatal respiratory distress syndrome, aspiration syndromes or neonatal maladaptation to extra-uterine life is difficult ; c) blood culture - the golden standard in neonatal sepsis diagnosis - provides late information, has a poor accuracy, and is not universally available; and d) up to date, there is no an ideal diagnostic tool for neonatal infection . Therefore, diagnosis of neonatal sepsis is still a challenge for neonatal medicine.

Antibiotic therapy is often initiated based upon clinical suspicion and/or the presence of risk factors, leading to excessive antibiotic therapy. Very often the diagnosis criteria for neonatal sepsis consists in documenting an infection in a newborn with severe systemic disease in which all possible noninfectious explanations for the patient's altered physiological status are either ruled out or unlikely.

The "gold standard", definitive test for neonatal sepsis is the isolation of the pathogen from blood. However, its accuracy is influenced by multiple factors a) contamination during sampling; b) sampling after antibiotic therapy was started; c) insufficient sampling volume; d) low colony count bacteremia. Accuracy of the blood culture varies between8 and 73% in various studies .

Despite hundreds of published studies, there is still no consensus regarding the best screening test or panel of tests for rapid detection of neonatal sepsis. Recently, new acute phase proteins, cytokines, cell surface antigens, and bacterial genome are used to improve the neonatal sepsis diagnosis but data are still under evaluation and most of these tests are either not clinically available or they are expensive .

Accumulating evidence indicates that the CBC is an effective predictor of prognosis and mortality in many disease states, including hematological disease, neoplasms, and severe infections. Therefore, non- specific changes in the CBC in critically ill neonates could be considered a key prognostic factor in the evaluation of survival prediction in these patients .

Some prognostic scoring systems with performance status, clinical symptoms and biochemical parameters help to guide accurate prediction of the prognosis, such as the acute physiology and chronic health evaluation, yet are considered too complex for general clinical use. Therefore, the prediction of clinical events with laboratory parameters, including complete blood cell count (CBC), has become an increased focus of research .

Total leukocyte count (TLC), total neutrophil count, ANC, immature neutrophil count, immature/total neutrophil ratio (I:T ratio), immature/mature neutrophil ratio (I:M ratio), neutrophil degenerative changes (vacuolization, toxic granulations, and Döhle bodies), and platelet count are the most used hematological parameters for Early Onset Sepsis evaluation . Most of the hematological screening panels for Early Onset Sepsis use a total leukocyte count < 5000 cells/mm3 or > 20.000 cells/mm3, an I:T ratio > 0.2, and total outside the normal range. TLC increases in severe neonatal infections (both mature and immature cells) possible secondary to growth factors and cytokine release that stimulate the bone marrow production.

Thrombocytopenia is one of the early but non-specific indicator of neonatal sepsis with or without DIC. It can be caused by bacterial, viral, fungal and parasitic infections and other non-infectious causes. The overall prevalence of thrombocytopenia in neonatal age group varies from1- 5%, and is reported to be much higher in newborns admitted to intensive care units, i.e. ranging from 22% to 35%. Severe thrombocytopenia (50000/mm3) was found to be present in 2.4% patients admitted in NICU.Bleeding is a major complication of thrombocytopenia but is generally limited to infants with count< 30000/mm3. Studies have shown that approximately 50% cases of culture proven of sepsis get thrombocytopenia .Changes in other platelet indices, like MPV(mean platelet volume) and PDW (platelet distribution width) have also been examined in relationship to neonatal sepsis in some studies .

Platelet indices (platelet counts, platelet distribution width-(PDW), mean platelet volume (MPV)) are one such set of parameters which can be helpful for the diagnosis and hence early treatment of neonatal sepsis. Advantages of platelet indices are that the sample for these can be drawn at the same time as that for other investigations and require no special sampling techniques and are easily available. Some studies had reported a low platelet counts, high mean platelet volume and platelet distribution width was observed in sepsis cases with a statistically significant difference as compared to controls .

Conditions
Neonatal Sepsis
Being tested
complete blood count
Keywords
neonatal sepsis, white blood cells, platelets
Medical subject headings
Neonatal Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • complete blood countDiagnostic test

    Also called blood culture

    complete blood count

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. white blood cells

    total leucocytic count

    Measured: one year

  2. white blood cells indices

    total neutrophil count

    Measured: one year

  3. Platelets indices

    Platelet count

    Measured: one year

  4. Platelets indices

    Platelet distribution width(PDW)

    Measured: one year

  5. Platelets indices

    Mean platelet volume

    Measured: one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Mar 2019
  2. Study start1 Apr 2019 (estimated)
  3. Primary completion30 Sep 2019 (estimated)
  4. Study completion31 Mar 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
100 participants (estimated)
Target duration
10 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT03880305
Sponsor's protocol ID
WBCPLATNS
Status last verified
Mar 2019
First submitted
13 Mar 2019
Last updated
19 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: all collected IPD

Questions about this trial

What is this clinical trial studying?

An observational study of Neonatal Sepsis, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Eslam A Roshdy (00201066962696, iroshdy92@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

white blood cells (time frame: one year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in